Relationship between Circulating FGF21 Concentrations and the Severity of Coronary Artery Damage in Subjects with Cardiovascular Disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Fibroblast growth factor (FGF) 21 is a recently established therapeutic target for treating metabolic syndromes, which include potential precursors to cardiovascular disease, suggesting a link between FGF21 and atherosclerosis. However, the association between serum FGF21 concentrations and coronary artery disease remain controversial. The aim of this study is to evaluate the association between circulating FGF21 concentrations and coronary artery lesions and clinical severity. Methods: We enrolled 137 subjects who underwent coronary angiography, due to suspected acute coronary syndrome (ACS), from December 2009 to July 2012. Serum FGF21 levels were measured. Coronary artery lesions and clinical severities of the subjects were evaluated using the SYNergy between percutaneous coronary intervention with (paclitaxel-eluting) TAXus stent and cardiac surgery (SYNTAX) and Global Registry of Acute Coronary Events (GRACE) scoring system, respectively. Results: After adjusting for established cardiovascular disease risk factors, including age, body mass index, total cholesterol, and low-density lipoprotein cholesterol, patients with coronary artery lesions (n=112 men) had significantly higher levels of FGF21 than individuals without such lesions (n=25; men) (377.1±20.1 pg/mL vs. 267.1±43.5 pg/mL; p=0.026). However, no correlations were found between serum levels of FGF21 and either the calculated STNTAX score (r=0.117; p=0.176) or GRACE risk score, which is a risk prediction tool applicable for ACS subjects (r=0.113; p=0.193). Conclusion: Although serum levels of FGF21 were higher in individuals with coronary lesions than in those without such lesions, FGF21 levels were not associated with angiographic severity.
Abstract
Objective: Fibroblast growth factor (FGF) 21 is a recently established therapeutic target for treating metabolic syndromes, which include potential precursors to cardiovascular disease, suggesting a link between FGF21 and atherosclerosis. However, the association between serum FGF21 concentrations and coronary artery disease remain controversial. The aim of this study is to evaluate the association between circulating FGF21 concentrations and coronary artery lesions and clinical severity. Methods: We enrolled 137 subjects who underwent coronary angiography, due to suspected acute coronary syndrome (ACS), from December 2009 to July 2012. Serum FGF21 levels were measured. Coronary artery lesions and clinical severities of the subjects were evaluated using the SYNergy between percutaneous coronary intervention with (paclitaxel-eluting) TAXus stent and cardiac surgery (SYNTAX) and Global Registry of Acute Coronary Events (GRACE) scoring system, respectively. Results: After adjusting for established cardiovascular disease risk factors, including age, body mass index, total cholesterol, and low-density lipoprotein cholesterol, patients with coronary artery lesions (n=112 men) had significantly higher levels of FGF21 than individuals without such lesions (n=25; men) (377.1±20.1 pg/mL vs. 267.1±43.5 pg/mL; p=0.026). However, no correlations were found between serum levels of FGF21 and either the calculated STNTAX score (r=0.117; p=0.176) or GRACE risk score, which is a risk prediction tool applicable for ACS subjects (r=0.113; p=0.193). Conclusion: Although serum levels of FGF21 were higher in individuals with coronary lesions than in those without such lesions, FGF21 levels were not associated with angiographic severity.
참고문헌 (21)
- Mathers CD, "Projections of global mortality and burden of disease from 2002 to 2030", PLoS Med, 3, pp.e442~ (2006)[DOI]
- Domouzoglou EM, "Fibroblast growth factors in cardiovascular disease: the emerging role of FGF21", Am J Physiol Heart Circ Physiol, 309, pp.H1029~H1038 (2015)[DOI]
- Kokkinos J, "The role of fibroblast growth factor 21 in atherosclerosis", Atherosclerosis, 257, pp.259~265 (2017)[DOI]
- Dostalova I, "Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity", type 2 diabetes mellitus, 2009, pp.58, 1~7
- Shen Y, "Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease", Cardiovasc Diabetol, 12, pp.124~ (2013)[DOI]
- 서지아, "Fibroblast Growth Factor 21: A Novel Metabolic Regulator", Diabetes and Metabolism Journal, 36(1), pp.26~28 (2012), 대한당뇨병학회
- Fukumoto S, "Actions and mode of actions of FGF19 subfamily members", Endocr J, 55, pp.23~31 (2008)[DOI]
- Gaich G, "The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes", Cell Metab, 18, pp.333~340 (2013)[DOI]
- Dushay J, "Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease", Gastroenterology, 139, pp.456~463 (2010)[DOI]
- 김원진, "Association between Serum Fibroblast Growth Factor 21 and Coronary Artery Disease in Patients with Type 2 Diabetes", Journal of Korean Medical Science, 30(5), pp.586~590 (2015), 대한의학회
- Lee Y, "Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status", Clin Endocrinol (Oxf), 80, pp.57~64 (2014)[DOI]
- Li Q, "Association between serum fibroblast growth factor 21 and mortality among patients with coronary artery disease", J Clin Endocrinol Metab, 101, pp.4886~4894 (2016)[DOI]
- Sianos G, "The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease", EuroIntervention, 1, pp.219~227 (2005)
- Kolovou GD, "Risk scores after acute coronary syndrome", Angiology, 68, pp.185~188 (2017)[DOI]
- Farooq V, "Widening clinical applications of the SYNTAX score", Heart, 100, pp.276~287 (2014)[DOI]
- Granger CB, "Predictors of hospital mortality in the global registry of acute coronary events", Arch Intern Med, 163, pp.2345~2353 (2003)[DOI]
- Lin Z, "Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile", PLoS One, 5, pp.e15534~ (2010)[DOI]
- Leigang Jin, "Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk", Diabetes and Metabolism Journal, 40(1), pp.22~31 (2016), 대한당뇨병학회[DOI]
- Chow WS, "Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors", Arterioscler Thromb Vasc Biol, 33, pp.2454~2459 (2013)[DOI]
- Lenart-Lipinska M, "Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up", Diabetes Res Clin Pract, 101, pp.194~200 (2013)[DOI]
- Andersen B, "Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers", Clin Endocrinol (Oxf), 75, pp.514~519 (2011)[DOI]